Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/18015
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Karunanayake, A. | en_US |
dc.contributor.author | Devanarayana, N.M. | en_US |
dc.contributor.author | de Silva, A. | en_US |
dc.contributor.author | Gunawardena, S. | en_US |
dc.contributor.author | Rajindrajith, S. | en_US |
dc.date.accessioned | 2017-11-15T09:20:09Z | en_US |
dc.date.available | 2017-11-15T09:20:09Z | en_US |
dc.date.issued | 2018 | en_US |
dc.identifier.citation | Journal of Pediatric Gastroenterology and Nutrition. 2018; 66(5):725-731 | en_US |
dc.identifier.issn | 0277-2116 (Print) | en_US |
dc.identifier.issn | 1536-4801 (Electronic) | en_US |
dc.identifier.issn | 0277-2116 (Linking) | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/18015 | en_US |
dc.description | Indexed In MEDLINE | en_US |
dc.description.abstract | OBJECTIVES: The aim of the study was to evaluate the therapeutic effect of domperidone on children with abdominal pain predominant functional gastrointestinal disorders (AP-FGIDs). METHODS: One hundred children (aged 5-12 years) fulfilling Rome III criteria for AP-FGIDs were randomized into 8 weeks of domperidone or placebo treatment. Primary outcomes defined were cure and patient-reported general improvement. Secondary outcomes were reduction in the severity of abdominal pain and increase in gastric motility. Patients were followed up for 6 months. RESULTS: Eighty-nine (42 in placebo group, 47 in domperidone group) completed the trial at 8 weeks. Seventy-nine completed the 6-month follow-up. When primary outcomes were assessed at 8 weeks, 37 (74%) in the domperidone group and 25 (50%) in the placebo group showed patient-reported general improvement (P = 0.013), whereas no significant difference was observed in cure (22 [44%] vs 14 [28%] P = 0.09). At 6-month follow-up 30 (60%) in the domperidone group and 19 (38%) in the placebo group reported cure (P = 0.028), whereas 44 (88%) in the domperidone group and 33 (66%) in the placebo group showed patient-reported general improvement (P = 0.009). When assessing secondary outcomes at 8 weeks, the domperidone group reported significant reduction in the severity of abdominal pain (54.1% vs 24.7%, P = 0.008) and an increase in the antral motility index (27.5% vs 7.2%, P = 0.029). None of the patients reported intervention-related adverse effects. CONCLUSIONS: Domperidone may be a safe and effective therapeutic modality to achieve a lasting remission of symptoms in children with AP-FGIDs. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.subject | Effect of domperidone | en_US |
dc.title | Randomized controlled clinical trial on value of domperidone in functional abdominal pain in children | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.